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Apoptosisnucleotide translocators (Ant) are bi-functional proteins that transport ADP and
ATP across the mitochondrial inner membrane, and regulate the mitochondrial permeability transition pore
(mtPTP) which initiates apoptosis. The mouse has three Ant isoforms: Ant1 expressed in heart, muscle, and
brain; Ant2 expressed in all tissues but muscle; and Ant4 expressed primarily in testis. Ant1-deﬁcient mice
manifest muscle and heart but not brain pathology. Brain Ant1 is induced by stress, while Ant2 is not. Ant1-
deﬁcient mice are resistant to death induced by systemic exposure to the brain excitotoxin, kainic acid (KA),
and their hippocampal and cortical neurons are signiﬁcantly more resistant to neuronal death induced by
glutamate, KA, and etoposide. The mitochondrial membrane potential of Ant1-deﬁcient brain mitochondria
is increased and the mtPTP is more resistance to Ca++ induced permeability transition. Hence, Ant1-
deﬁciency may protect the brain from excitotoxicity by desensitizing the mtPTP and by blocking the pro-
apoptotic induction of Ant1 by stress.
© 2008 Published by Elsevier B.V.1. IntroductionThe mitochondrial adenine nucleotide translocator (Ant or ADP/
ATP translocase) is themost abundantmitochondrial innermembrane
proteinwhose primary function is to exchange ADP and ATP across the
mitochondrial inner membrane [1]. Humans have three main ANTs
plus a testis isoform, while mouse has two main isoforms, Ant1 and
Ant2, plus a testis isoform, Ant4. In mouse, Ant1 is expressed in the
skeletal muscle, heart, and brain, while Ant2 is expressed in all tissues
except skeletal muscle [2–7].
The Ants interact with a multi-polypeptide complex which spans
the mitochondrial inner and outer membranes, the mitochondrial
permeability transition pore (mtPTP) [8–10]. While the Ants do not
appear to provide the actual ion channels of the mtPTP, they play an
important role in regulating the mtPTP in response to calcium and
adenine nucleotides [11].
Mice in which the Ant1 gene (Ant1) is insertionally inactivated
(Ant1-deﬁcient mice) develop mitochondrial myopathy associated
with ragged-red ﬁbers and abnormal mitochondria and a hyper-
trophic cardiomyopathy [12]. The muscle of Ant1−/−mice exhibit anMitochondrial Medicine and
, Irvine, Irvine, CA 92697-3940,
lsevier B.V.induction of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA)
oxidative phosphorylation (OXPHOS) gene expression, antioxidant
defense proteins, and anti-apoptotic factors [13–15]. Yet, Ant1-
deﬁcient mice show no overt evidence of neurological disease.
To determine why the muscle and heart are affected in Ant1-
deﬁcient mice but the brain is not, we examined the response of Ant1-
deﬁcient mice to excitotoxic KA brain insult and Ant1-deﬁcient
cultured mouse neurons to excitotoxins (glutamate and KA) and the
DNA damaging agent (etoposide). Ant1-deﬁcient mice were as prone
as wild type mice to KA induced seizures, but were more resistant to
KA-induced death. Ant1-deﬁcient neurons were resistant to gluta-
mate and KA induced death and their mitochondria had increased
membrane potential, decreased ATP, and partially stabilized mtPTP.
These results suggest that the loss of Ant1 stabilizes the mtPTP against
Ca++ activation. Therefore, Ant1-deﬁcient mice may be resistant to
neurodegeneration because the mtPTPs of their neurons are less
prone to permeability transition and to stress-induced induction of
Ant1 and initiation of apoptosis.
2. Materials and methods
2.1. Ant1-deﬁcient mice, brain expression of Ants, and kainic acid toxicity
2.1.1. Mice and mouse handling
Ant1-deﬁcient mice on C57BL/6J2z background were previously
prepared by the insertional inactivation of the Ant1 gene by in-frame
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neomycin fusion protein (βgeo) [12]. Mice were maintained at
20–23 °C on a 13-hour light/11-hour dark cycle using the procedures
mandated by the National Institutes of Health guidelines and the
University of California Institutional Animal Care and Use Committee.
2.1.2. Regional brain expression of Ant1
The regional expression of Ant1 was investigated by staining brain
sections of heterozygous Ant1βgeo mice for expression of β-galactosi-
dase transcribed from the Ant1 gene promoter [12]. Mouse brains
were serially cryostat sectioned (15 μm) in either the coronal or the
sagittal plane, the sections ﬁxed in 2% formaldehyde and 1%
glutaraldehyde in saline buffer, the sections rinsed and stained with
X-gal solution for 24 h at 37 °C, and then counterstained with Nuclear
Fast Red [16].
2.1.3. Kainic acid excitotoxicity
The tendency of Ant1-deﬁcient and control mice to develop
seizures and to die in response to the brain excitotoxic agent kainic
acid (KA) was investigated by a single intraperitoneal injection of
35 mg/kg KA into age-matched Ant1-deﬁcient and control animals.
Mice were then monitored continuously for 3–4 h. At 2 h they were
evaluated for the onset and extent of seizure activity and animal
survival. Seizure activity was rated as immobility, stage 1; forelimb
and/or tail extension and rigid posture, stage 2; repetitivemovements
and head bobbing, stage 3; rearing and falling, stage 4; continuous
rearing and falling, stage 5; severe tonic–clonic seizures, stage 6 [17].
Survival was assessed at 2 and 48 h.Fig. 1. Ant1 expression in the mouse brain and hippocampal neurons. X-gal stained brain an
mouse brain and (b) a sagittal section of cerebellumwere ﬁxed and stained with X-gal, then
(EG), III. External Pyramidal layer (EP), IV. Internal Granular layer (IG), V. Internal Pyramidal
dentate gyrus, W: white matter, G: granular layer, P: purkinje cell layer, M: molecular layer. (
with X-gal. Scale bar: 100 μm (A, B), 20 μm.2.1.4. Western blot analysis of Ant1 and Ant2 protein levels
Relative protein levels were assessed by Western blots prepared
from 50 μg solubilized protein using as primary antibodies rabbit
polyclonal antibodies against Ant1 and Ant2 [12], and a mouse porin
31HL monoclonal antibody (CalBiochem, 89-173/016; 1:10000 dilu-
tion). Western blots were immunoreacted with primary antibodies
overnight at 4 °C, stained with horse radish peroxidase (HRP)-
conjugated secondary antibody (the species origin of the secondary
antibodies varied depending on the origin of the primary antibody),
the antibody staining detected by chemiluminescence (Amersham),
and quantiﬁed by densitometric analysis.
2.2. Primary neuronal cell cultures: treatments and cell death
2.2.1. Preparation of primary neuronal cultures
Primary mouse embryonic brain cell cultures were established
from dissociated 18 day embryos [18]. The hippocampus and cortex
were removed and incubated for 15 min in calcium and magnesium-
free Hank's Balanced Saline Solution (Mediatech, Inc.) containing
0.25% trypsin. The cells were dissociated and plated into poly-D-
Lysine-coated plastic or glass-bottom culture dishes containing
Neurobasal Medium supplemented with 10% B27, 2 mM L-glutamine,
and 25 μM glutamate. Following cell attachment, the culture medium
was replaced with medium without glutamate. Toxicity experiments
were performed after 7 days in culture (7 DIC), a time during which
neurons are vulnerable to excitotoxic and apoptotic insults [19,20].
Quantiﬁcation of neuron survival in hippocampal cell cultures [21]
involved pre-markingmicroscope ﬁelds for the number of undamagedd hippocampal neurons taken from homozygous Ant1βgeo. (a) A coronal section of adult
counterstained with Nuclear Fast Red. I. Molecular layer (M), II. External Granular layer
layer (IP), VI. Fusiform layer (F), WM: white matter, Rt: reticular thalamic nucleus, DG:
C) Hippocampal neurons cultured from embryonic brains of Ant1βgeo mice and stained
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monitoring the number of surviving cells over time. Neurons with
intact neurites and a cell body that was smooth and round to oval in
shape were considered viable, whereas neurons with beaded or
fragmented neurites and a cell body that was shrunken and rough in
appearance were considered nonviable. Overall cell viability was
assessed by the release into the medium of lactate dehydrogenase
assay (LDH kit, Roche), performed in a 96 well assay format. The LDH
activities were normalized as the percentage of control of DMSO-
treated control groups.
2.2.2. Measurement of cellular ATP levels
Neuronal cell ATP levels were assayed using a luciferin/luciferase-
based assay. Neuronal cell cultures were rinsed with phosphate
buffered saline and lysed with 0.2 ml lysis reagent (Roche, Mannheim,
Germany). The ATP concentrations were quantiﬁed using the ATP
Bioluminescence Assay Kit CLS II (Roche, Mannheim, Germany) with a
Sirius-Luminometer (Berthold Detection Systems). Experimental
values were compared to an ATP standard curve with values reported
as nmol ATP per mg protein [22].
2.2.3. Rhodamine 123 evaluation of mitochondrial membrane potential
and mtPTP activation
Mitochondria from the forebrain (whole brain minus the cere-
bellum and brain stem)were isolated following euthanasia by cervical
dislocation. The forebrains were homogenized with six hand strokes
of a glass-Teﬂon dounce homogenizer containing 10 ml of isolation
buffer (225 mMmannitol, 75 mM sucrose, 10 mMMOPS, 1 mM EGTA,
0.5% BSA, pH 7.2). The homogenate was then centrifuged for 5 min at
4 °C at 1000 ×g, the supernatant retained and centrifuged for 15min at
4 °C at 8000 ×g, and the pellet re-suspended in approximated 300 μl of
isolation buffer. Protein was measured by pelleting the mitochondria
in 4 μl aliquots, 2 min at 10,000 ×g, resuspending the pellet in 200 μl of
isolation buffer without BSA by sonication and quantiﬁed using the
Bradford method. Mitochondrial membrane potential and perme-
ability transition were measured using the ﬂuorescent probe
rhodamine 123 [23] with a Perkin Elmer LS50B luminescent spectro-
photometer set at 490 nm excitation and 535 nm emission with
stirring. One milligram of mitochondrial protein was added to 3 ml of
reaction buffer (250 mM sucrose, 10 mMMOPS, 2 mM K2HPO4, 5 mM
succinate, pH 7.2) at 30 °C. Fluorescencewas allowed to stabilized, and
then CaCl2 was added in sequential aliquots of 15 or 25 nmol, each
associated with a transient increase in ﬂuorescence. Activation of the
mtPTP, and collapse of the electrochemical gradient was signaled by
the maximum rise and stabilization of ﬂuorescence.
Rhodamine 123 concentrations were quantiﬁed using a standard
curve, and membrane potentials were calculated by the Nernst
equation with the concentration outside being measured directly byFig. 2. Excitatory challenge induces Ant1 but not Ant2 protein levels in cultured neurons an
and Ant2 protein levels assessed by Western blot relative to porin. (b) Mice were challenged
blot relative to porin. The data were conﬁrmed by three independent experimentsthe minimum level of ﬂuorescence after the addition of mitochondria
(Foutside), and the concentration inside being the difference between
the total concentration (maximum ﬂuorescence obtained after CaCl2
addition, Ftotal) and the concentration outside. The mitochondrial
volume was assumed to be 1 μl/μg [24].
3. Results
3.1. Expression of Ant1 in brain and hippocampal neurons
The regional distribution of Ant1 expression in the brain was
determined by staining brain sections from heterozygous Ant1βgeo
mice with X-gal to detect β-galactosidase transcribed from the
endogenous Ant1 promoter. Ant1 was found to be expressed
throughout the adult Ant1βgeo brain in both neurons and glial cells.
It was highly expressed in the external and internal pyramidal
neurons and in cortical layers III and V. Higher staining was seen in the
reticular thalamic nucleus and lateral ventricles. Ant1 expression was
also seen in the hippocampal pyramidal neurons (CA1, CA2, CA3 and
hilus), but not in the granule cells in the dentate gyrus (Fig. 1a).
However, the absence of β-galactosidase staining in the granule cells
in the dentate gyrus is probably the result of suppression of expression
of the βgeo fusion protein in these cells rather than lack of
transcription from the Ant1 promoter [25]. Sagittal sections of
cerebellum showed that Ant1 was highly expressed in the Purkinje
and granule cell layers, and in the fastigal nuclei (Fig. 1b).
To conﬁrm that neurons express Ant1, primary cultured hippo-
campal neurons differentiated from the embryonic brains of Ant1βgeo
mice were stained with X-gal and found to be strongly positive.
Moreover, the fusion protein was localized to the neuronal mitochon-
dria, presumably targeted there by the ﬁrst third of the Ant1 protein
that was included in the fusion protein (Fig. 1c) [12].
Previously, we observed that Ant1 is up-regulated in response to
cortical lesions resulting in glial scarring [26] and that this is mediated
through TGFβ-Smad signal transduction pathway [27]. To determine if
Ant1 is also inducible in neurons, we used Western blots to examine
the levels of Ant1 and Ant2 in cultured hippocampal neurons,
following 24 h exposure to 100 μM glutamate. After glutamate
exposure, Ant1 increased in the neurons, but Ant2 levels were
unaffected (Fig. 2a). This was also true for the whole brain since
mice injected with the neuronal excitotoxin KA showed an increase in
Ant1 protein, but not in Ant2 protein (Fig. 2b).
3.2. Ant1-deﬁcient mice are more resistant KA induced mortality
To determine if Ant1-deﬁciency affects the brain's susceptibility to
excitotoxic challenge, we injected age-matched Ant1-deﬁcient and
control mice with a single dose of KA and then monitored the seizured brains: (a) cultured hippocampal neurons were challenged with glutamate, and Ant1
with KA, the hippocampi isolated, and the levels of Ant1 and Ant2 assessed byWestern
Table 1
Seizure activity and mortality in mice 2 h after systemic KA administration
Group Stage 3 or above seizures Mortality
#/N % #/N %
Wild type 12/12 100 11/12 92
Ant1-KO 9/10 90 4/10 40a
4/9 44b
KA was administered systemically to mice by intraperitoneal injection of 35 mg/kg.
Ant1-KO=Ant1-knockout mice.
a Mortality of all mice injected with KA, relative to wild type P=0.01.
b Mortality of mice showing stage 3 seizure activity or above following KA injection,
relative to wild type P=0.02.
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injection, 90% of the Ant1-deﬁcient (9 of 10) mice and 100% of the
control mice exhibited stage 3 or above seizure activity (Table 1).
However, 92% (11 of 12) of the control mice died, while only 40% (4 of
10) of the ANT1-deﬁcient mice died, a signiﬁcant difference (Pb0.01)
(Table 1). This mortality difference was signiﬁcant even when onlyFig. 3. Ant1-deﬁciency protects cultured hippocampal neurons from excitotoxic death.
Cultured (a) hippocampal and (b) cortical neurons were treated for 24 h with
glutamate, and neuronal survival assessed by phase-contrast photomicrographs (four to
ﬁve ﬁelds per culture dish, approximately 20–40 neurons present in each ﬁeld). Results
are the mean±SD of 5 to 6 cultures. (⁎⁎Pb0.01 compared to the wild type).mice showing stage 3 seizure activities or above were included in the
analysis with 4/9 stage 3 Ant1-deﬁcient mice versus 10/12 stage 3
control mice having died. By 48 h post-injection an additional Ant1-
deﬁcient mouse had died, yet the difference in mortality was still
signiﬁcantly different, Pb0.02 (Chi Square) or Pb0.05 (Fisher Exact
Test). Thus, Ant1-deﬁciency it is strongly protective of animal
mortality following KA excitotoxicity, though Ant1-deﬁciency is not
protective for KA-induced seizures.
3.3. Ant1-deﬁcient neurons are more resistant to glutamate-induced
excitotoxicity
To examine the role of Ant1 in neuronal survival after excitotoxic
challenge, we exposed cultured hippocampal and cortical neurons to
increasing concentrations of glutamate. Glutamate binds to the NMDA
receptor, resulting in the inﬂux of Ca++ into the cells and leading to
increased ROS production and excitotoxic cell death [28]. After 24 h of
20 to 400 μM glutamate exposure, about twice as many of the Ant1-
deﬁcient hippocampal neurons survived as undamaged neurons in
pre-marked microscopic ﬁelds as wild type neurons (Fig. 3a). This cell
survival data was conﬁrmed by cell lysis release of LDH into the
medium (data not shown). Increased glutamate resistance was also
seen in Ant1-deﬁcient cortical neurons (Fig. 3b). Therefore, Ant1-
deﬁcient neurons are signiﬁcantly more resistant to glutamate
excitotoxicity than the wild type neurons, suggesting that the loss of
Ant1 is neuroprotective.
3.4. Ant1-deﬁcient neurons are more resistant to DNA damage-induced
cell death
To determine if Ant1-deﬁciency protected neurons to other
initiators of cell death, we exposed cortical and hippocampal Ant1-
deﬁcient and wild type neurons to the topoisomerase II inhibitor,
etoposide [29]. Cell lysis was quantiﬁed through the release of LDH
into the medium after 24 h. Following etoposide exposure, wild type
cortical and hippocampal neurons released almost twice as much
LDH as did the Ant1-deﬁcient neurons (Fig. 4). This etoposide-
induced neuronal death was associated with PARP cleavage, detected
using Western blots (data not shown). Thus, Ant1-deﬁcient cells
were more resistant to etoposide induced cell death than wild type
neurons (Fig. 4).Fig. 4. Ant1-deﬁciency protects cultured neurons from death induced by DNA damage.
Neurons were exposed to 10 μM etoposide for 24 h, and cell viability was assessed by
LDH release. Values are the means and SD of determinations made in six different
cultures. ⁎⁎Pb0.01 compared to corresponding value for cultures from wild type mice.
Fig. 6. Monitoring membrane potential and mtPTP transition in response to Ca++
additions and mtPTP transition. (a) Mitochondrial membrane potentials of Ant1-
deﬁcient and wild type brain mitochondria (⁎⁎Pb0.0001). (b) Additions of mitochon-
dria (MT) and CaCl2 (Ca++) are indicated as are the points at which the ﬂuorescence
readings, Foutside and Ftotal, were made. (c) The Ca++ required to initiate mtPTP
transition inmitochondria isolated fromAnt1-deﬁcient and wild type brains (⁎Pb0.05).
Results are means and SD, n=12 per genotype.
Fig. 5. Lower intracellular ATP levels in cortical and hippocampal neurons of Ant1-
deﬁcient mice. Values are the mean and SD of determinations made in 4 different
cultures. Ant1-deﬁcient cortical neurons, Pb0.05 and Ant1-deﬁcient hippocampal
neurons (Pb0.001) relative to wild type neurons.
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To determine if Ant1-deﬁciency reduced cellular ATP levels, we
used a luciferase assay to measure ATP concentrations in cell lysates.
This revealed that the ATP levels were decreased by approximately
20% in the embryonic cortical neurons (pb0.05) and 67% in
hippocampal neurons (pb0.001) derived from Ant1-deﬁcient brains
(Fig. 5). The residual levels of ATP sustained by the Ant1-deﬁcient
neurons probably reﬂect continued ADP–ATP exchange through Ant2
and ATP generation by glycolysis.
3.6. Ant1-deﬁcient neuronal mitochondria are resistant to Ca++-induced
mtPTP opening
Mitochondria isolated from the brains of Ant1-deﬁcient and wild
type mice were assayed for the mitochondrial inner membrane
electrochemical potential and sensitivity of the mtPTP to Ca++
activation, both monitored by the uptake and release of rhodamine
123 in energized mitochondria. Forebrain mitochondria from Ant1-
deﬁcient mice were found to have a membrane potential of 193 mV
while wild type mitochondria had a membrane potential of 184 mV
(Fig. 6a). This approximately 9 mV/mg protein increase in mitochon-
drial inner membrane potential is highly signiﬁcant and may reﬂect a
reduction in the proton leak through the inner membrane due to loss
of the Ant1 [30].
To measure the potential of the Ant1-deﬁcient mtPTP to undergo
permeability transition, the amount of Ca++ was quantiﬁed that was
required to cause an irreversible release of rhodamine 123 from the
mitochondria due to the collapse of the electrochemical gradient
(Fig. 6b). The Ant1-deﬁcient mitochondria required 72 nmol of Ca++
to initiate mtPTP transition while wild type mitochondria required
60 nmol, approximately 20% less (Pb0.05) (Fig. 6c). Hence themtPTPs
of the Ant1-deﬁcient mitochondria are signiﬁcantly more resistant to
Ca++-induced permeability transition. Still, the increased resistance
of the partially Ant1-deﬁcient brain mitochondria (Ant1 null, Ant2
positive) to Ca++ induced permeability transitionwas much less than
that required to activate the completely Ant1-deﬁcient liver
mitochondria (Ant1 null, Ant2 null) [11], suggesting that both Ant1
and Ant2 may contribute to the Ca++ sensitivity of the mtPTP.
4. Discussion
Wehad previously shown that Ant1 is strongly expressed inmouse
skeletal muscle, heart, and brain [5,12]; and have now determined theregional expression of Ant1 in the brain and conﬁrmed that Ant1 is
strongly expressed in neurons. Even so, while inactivation of Ant1 in
mouse [12] and ANT1 in humans [31] results in severe muscle and
heart pathology, neither mice nor humans show an overt neurological
phenotype. This is particularly remarkable since Ant1-deﬁciency in
the mouse cortical and hippocampal neurons results in a 1/5 and 2/3
reduction in ATP levels, respectively. This reduction in cellular ATP
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mitochondrial inner membrane potential of Ant1-deﬁcient mitochon-
dria is signiﬁcantly higher than that found in wild type mitochondria,
a result consistent with our previous observation that Ant1 makes a
signiﬁcant contribution to the mitochondrial inner membrane basal
proton leak which inactivation of Ant1 blocks [30].
The Ant1-deﬁcient mouse is also signiﬁcantly more resistant to
KA-induced neuronal excitotoxicity and death than wild type mice,
and Ant1-deﬁcient cortical and hippocampal neurons are more
resistance to glutamate and KA induced excitotoxic cell death as
well as etoposide-induced cell death. Isolated Ant1-deﬁcient brain
mitochondria are also signiﬁcantly more resistance to Ca++ induced
mtPTP permeability transition than controls [21,32–35]. Since both
etoposide-induced cell death and Ca++-induced permeability transi-
tion of cultured rodent embryonic neurons has been shown to be
inhibited by cyclosporin A [36] and etoposide induced cell death
shown to be associatedwith increased cell reactivity to annexin V [36],
it would seem that Ant1 is important in excitotoxic Ca++-induced
mtPTP permeability transition leading to cell death by apoptosis.
These observations lead to the question, why are Ant1-deﬁcient
brains resistant to excitotoxic insult? We have previously shown that
Ant1, but not Ant2, is induced by brain trauma, medicated by TGFβ
and the Smad pathway [26,27]. Furthermore, it has been reported that
increased expression of Ant1 achieved by transfection of cultured cells
is pro-apoptotic [37]. Therefore, we might hypothesize that Ant1 is
bi-functional in the brain. Under normal circumstances, Ant1 func-
tions to export mitochondrial ATP into the nucleus–cytosol compart-
ment. When the brain is stressed, TGFβ and the Smads are activated,
inducing Ant1 to transport out more mitochondrial ATP to the
nuclear–cytosol to facilitate repair and recovery. However, if the
damage to the cell is sufﬁcient to compromise mitochondrial ATP
production, then induction of Ant1 cannot increase ATP levels and
does not resolve the cellular problem. Since the accumulation of such
energetically defective cells would erode organ function, the con-
tinued induction of Ant1 ultimately activates the mtPTP, resulting in
the elimination of the defective cell by apoptosis. While this is an
optimal strategy at the individual cell level, generalized brain insults
such as those resulting from KA excitotoxicity or ischemic stroke can
result in pan-neuronal apoptosis, causing destruction of the brain
function and death. Inactivation of Ant1 or inhibition of the mtPTP
[38] may then block this catastrophic outcome.
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